Hesperos的芯片可模拟药物在人体内心脏和肝脏毒性,未来可用于预测临床结果

2019-07-05 不详 MedSci原创

发表在Nature Scientific Reports杂志上最新研究显示,Hesperos 公司的"human-on-a-chip"芯片装置通过模拟心脏和肝脏,可以测量两种已知的可可损害心脏的小分子药物浓度和代谢,并能够提供对人体毒性的准确数据。

发表在Nature Scientific Reports杂志上最新研究显示,Hesperos 公司的"human-on-a-chip"芯片装置通过模拟心脏和肝脏,可以测量两种已知的可损害心脏和肝脏的小分子药物浓度和代谢,并提供对人体毒性的准确数据。

Hesperos表示,这是"体外芯片系统首次被证明能够预测人体内的结果,未来可能会用于预测临床试验结果。"

Hesperos首席执行官兼康奈尔大学名誉教授Michael Shuler博士说:"在体外检测药代动力学/药效学(PKPD)关系的能力,将使我们能够在体内评价之前了解药物的复杂行为,从而节省大量成本和时间。"

"我们很高兴这种技术未来可以用于提高候选药物在临床试验过程中获得成功的可能性。"

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1785834, encodeId=f3c71e858346d, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Jul 23 02:12:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898829, encodeId=c0781898829ee, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Oct 02 21:12:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728040, encodeId=80f51e2804089, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 12 05:12:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364503, encodeId=8d481364503de, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jul 07 07:12:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458971, encodeId=237d14589e1fe, content=<a href='/topic/show?id=53cc8691532' target=_blank style='color:#2F92EE;'>#芯片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86915, encryptionId=53cc8691532, topicName=芯片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bf76117088, createdName=lixiaol, createdTime=Sun Jul 07 07:12:00 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2019-07-23 shenxlcyp
  2. [GetPortalCommentsPageByObjectIdResponse(id=1785834, encodeId=f3c71e858346d, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Jul 23 02:12:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898829, encodeId=c0781898829ee, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Oct 02 21:12:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728040, encodeId=80f51e2804089, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 12 05:12:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364503, encodeId=8d481364503de, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jul 07 07:12:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458971, encodeId=237d14589e1fe, content=<a href='/topic/show?id=53cc8691532' target=_blank style='color:#2F92EE;'>#芯片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86915, encryptionId=53cc8691532, topicName=芯片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bf76117088, createdName=lixiaol, createdTime=Sun Jul 07 07:12:00 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1785834, encodeId=f3c71e858346d, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Jul 23 02:12:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898829, encodeId=c0781898829ee, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Oct 02 21:12:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728040, encodeId=80f51e2804089, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 12 05:12:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364503, encodeId=8d481364503de, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jul 07 07:12:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458971, encodeId=237d14589e1fe, content=<a href='/topic/show?id=53cc8691532' target=_blank style='color:#2F92EE;'>#芯片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86915, encryptionId=53cc8691532, topicName=芯片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bf76117088, createdName=lixiaol, createdTime=Sun Jul 07 07:12:00 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2019-12-12 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1785834, encodeId=f3c71e858346d, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Jul 23 02:12:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898829, encodeId=c0781898829ee, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Oct 02 21:12:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728040, encodeId=80f51e2804089, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 12 05:12:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364503, encodeId=8d481364503de, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jul 07 07:12:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458971, encodeId=237d14589e1fe, content=<a href='/topic/show?id=53cc8691532' target=_blank style='color:#2F92EE;'>#芯片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86915, encryptionId=53cc8691532, topicName=芯片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bf76117088, createdName=lixiaol, createdTime=Sun Jul 07 07:12:00 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2019-07-07 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1785834, encodeId=f3c71e858346d, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Jul 23 02:12:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898829, encodeId=c0781898829ee, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Oct 02 21:12:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728040, encodeId=80f51e2804089, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 12 05:12:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364503, encodeId=8d481364503de, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Jul 07 07:12:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458971, encodeId=237d14589e1fe, content=<a href='/topic/show?id=53cc8691532' target=_blank style='color:#2F92EE;'>#芯片#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86915, encryptionId=53cc8691532, topicName=芯片)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bf76117088, createdName=lixiaol, createdTime=Sun Jul 07 07:12:00 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2019-07-07 lixiaol

相关资讯

利用小鼠的神经元,他造出世界上**款有“嗅觉”的芯片

芯片通常是具有强大计算和存储能力的载体。按照不确切的说法,我们可以说它具有数字化的“理性”计算、推理能力。今天的人工智能带给我们眼花缭乱的各种惊喜,基础的条件之一便是芯片的强大计算能力。可是,芯片能不能模仿人类的感官能力呢?比如说嗅觉,有人在做饭,香喷喷的饭菜端上桌子,旁边的机器里有这么块芯片,然后机器觉得饿了,偷吃了你两口麻辣小龙虾。再比如说,有人放屁了,这个机器觉得难受,就自己跑远了,离开无色

Rsc Advances:监测抗癌药物毒副作用的“体内芯片”装置

京都大学日本综合细胞材料科学研究所(iCeMS)的研究人员设计了一种能够测试药物对人体细胞的副作用的小型“体内芯片”装置。该装置解决了当前类似的微流体装置的一些问题,并为下一代临床前药物测试提供了希望。

Cell Stem Cell:人类自身干细胞作的血脑屏障芯片

位于洛杉矶的Ben Gurion大学(BGU)和Cedars Sinai医学中心的研究人员首次复制了患者的血脑屏障(BBB),创造了用干细胞制作的人类BBB芯片,这是一项可用于开发个性化药物和研究大脑疾病的新技术。

PNAS:益生菌不常有益

事物的发展往往具有两面性。近日一项研究表明,益生菌可能不总是对我们的健康有益:通过使用一种新型人类“肠道炎症芯片”技术,奥斯汀大学的研究人员发现,只有当肠道上皮完好无损时,益生菌才可能有利于肠道健康;当肠道屏障已经受损时,益生菌可能会造成更多的伤害。

癌症生物医药“缺芯”之痛:“用别人的枪打别人的靶”

当IC行业“缺芯”之痛触动国人的时候,一场生物医药产业的“芯片”竞争已悄然开始。自主创新能力不足一直是我国生物医药产业的发展之痛。痛点之一,是有生物医药产业“原始芯片”之称的细胞模型。细胞模型是生物医学基础研究和药物研发的核心要素与战略性源头资源,决定着生物医药产业的原始创新能力。我国细胞模型一直受制于人,成为制约我国生物医药产业的“卡脖子”环节。《了望》新闻周刊记者近日从中科院合肥物质科学

人体植入芯片:未来已来,风险仍在

科幻大片中常常有这样的桥段,主角植入芯片改造身体,最终获得了超能力,变得无所不能。对大多数普通人来说,人体植入芯片像是遥不可及的黑科技。近日,欢聚时代(YY)联合创始人、董事长兼CEO李学凌在微信朋友圈自曝身体植入芯片,这一消息让人觉得,这个黑科技离现实似乎没那么遥远。